Compare TOVX & AIFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOVX | AIFA |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 14.7M |
| IPO Year | 2012 | 2017 |
| Metric | TOVX | AIFA |
|---|---|---|
| Price | $0.23 | $2.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 41.7K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $1.72 |
| 52 Week High | $0.86 | $2.53 |
| Indicator | TOVX | AIFA |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 37.38 |
| Support Level | $0.22 | $1.72 |
| Resistance Level | $0.27 | $2.19 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 17.97 | 50.81 |
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.